KRAS and the Reality of Personalized Medicine in Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

KRAS and the Reality of Personalized Medicine in Non-Small Cell Lung Cancer

Published:2016-01 Issue:1 Volume:22 Page:380-387
ISSN:1076-1551
Container-title:Molecular Medicine
language:en
Short-container-title:Mol Med

Author:

Kilgoz Havva O,Bender Guzide,Scandura Joseph M,Viale Agnes,Taneri Bahar

Publisher

Springer Science and Business Media LLC

Subject

Genetics(clinical),Genetics,Molecular Biology,Molecular Medicine

Link

http://link.springer.com/content/pdf/10.2119/molmed.2016.00151.pdf

Reference55 articles.

1. 1. My Cancer Genome online. c2010-2016. Nashville (TN): Vanderbilt-Ingram Cancer Center

2. 2. [accessed 2016 Jan 8]. http://www.mycancergenome.org.

3. Cancer Research UK online. c2013. London (UK): British Journal of Cancer, National Cancer Research Institute, Cancer Research Technology; [accessed 2016 Feb 9]. http://www.cancerresearchuk.org.

4. American Cancer Society online. c2016. New York (NY): National Health Council, Health On The Net, Better Business Bureau; [accessed 2016 Feb 5]. http://www.cancer.org.

5. World Health Organization online. c2016. Geneva (Switzerland): Worldwide Collaboration Centers; [accessed 2016 Feb 9]. http://www.who.int.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CRISPR and KRAS: a match yet to be made;Journal of Biomedical Science;2021-11-15

2. Magnesium intake and lung cancer risk: A systematic review and meta-analysis;International Journal for Vitamin and Nutrition Research;2021-09

3. The Outer Retinal Membrane Protein 1 Could Inhibit Lung Cancer Progression as a Tumor Suppressor;Computational and Mathematical Methods in Medicine;2021-02-17

4. Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China;BMJ Open;2020-11

5. Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis;Clinical Drug Investigation;2019-11-02